Toronto SickKids Hospital
Welcome,         Profile    Billing    Logout  
 6 Trials 
4 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Griffiths, Anne
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
Walters, Thomas
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
NCT06164743: Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Completed
2
91
US
VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
VivaVision Biotech, Inc
Inflammation
05/24
05/24
NCT06394973: Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

Active, not recruiting
2
126
US
T4090 0.2%, T4090 0.3%, Rhopressa®
Laboratoires Thea
Glaucoma, Ocular Hypertension
05/25
05/25
Bearup, Richelle
No trials found
McKay, Hayley
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Griffiths, Anne
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
Walters, Thomas
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
NCT06164743: Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Completed
2
91
US
VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
VivaVision Biotech, Inc
Inflammation
05/24
05/24
NCT06394973: Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

Active, not recruiting
2
126
US
T4090 0.2%, T4090 0.3%, Rhopressa®
Laboratoires Thea
Glaucoma, Ocular Hypertension
05/25
05/25
Bearup, Richelle
No trials found
McKay, Hayley
No trials found

Download Options